CUTISS is the only late-stage clinical TechBio company pioneering a personalized skin tissue therapy through bioengineering and automation.

We are transforming skin surgery by developing the first true living human skin on demand, enabling personalized, scalable solutions for a broad range of indications, with attractive unit economics and strong commercial potential:

• Game-changing BIO innovation in skin surgery: denovoSkin™ is in EMA-authorized Phase 3 trials under Orphan Drug Designation. This follows exceptional safety and efficacy results from:
  • Phase 1 in burns and reconstructions
  • Phase 2 in burns
  • Phase 2 in reconstructions
• US market breakthrough: Successfully treated our first patient in Boston, a pediatric patient.
• Scalable TECH: Pioneering the automation of personalized skin production and beyond.
• Strategic expansion into advanced dermatology: Acquired exclusive rights for VitiCell®, a CE-marked medical device for skin pigmentation restoration.
• Beyond Earth: Advanced space research on wound healing and aging (read here).

Current investment opportunity

With $94M raised to date (including $10M non-dilutive funds), our backers include Giammaria Giuliani and the Wyss Foundation Boston. We are now raising the second tranche of our Series C round, building on a successful $25M first tranche in 2024.

For more information, please contact our CEO, Dr. Daniela Marino.